Non-Alcoholic Fatty Liver Disease (NAFLD) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Kowa Company, Ltd., Huons Co., Ltd., Phenex Pharmaceuticals, Pfizer, PharmaKing, Future Medicine, Me

DelveInsight's "Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report:
• The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• NAFLD is the most prevalent chronic liver disease in the US, claims the American Liver Foundation (n.d.). About 25% of American individuals are thought to have NAFLD
• In the general population of Northern Italy: the Bagnacavallo Study, Foschi et al. (2019) found that the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in people with compared to those without altered liver enzymes
• In September 2022, If lanifibranor is approved, Inventiva and Chia Tai-Tianqing Pharmaceutical Group will work together to develop and market it in mainland China, Hong Kong, Macau, and Taiwan for the treatment of nonalcoholic steatohepatitis and possibly other metabolic diseases.
• In May 2022, Hepion Pharmaceuticals and HepQuant, a privately held firm with headquarters in Denver with innovative, unique investigational technology for assessing liver function and health in patients with chronic liver disorders, have collaborated clinically. Beginning in Q3 of this year, Hepion will include the HepQuant ''SHUNT'' test in a focused Phase IIb clinical trial in people with suspected NASH F3
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Abbott, Madrigal Pharmaceuticals, Kowa Company, Ltd., Huons Co., Ltd., Phenex Pharmaceuticals, Pfizer, PharmaKing, Future Medicine, Merck Sharp & Dohme, Norgine, Dong-A ST Co., Ltd., Novartis, MediciNova, GlaxoSmithKline, Sagimet Biosciences Inc., Conatus Pharmaceuticals, Inventiva Pharma, Amylin Pharma, Boehringer Ingelheim, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Obeticholicacid (OCA), Pegozafermin, SAMe 1000mg, Resmetirom, K-877, HL tablet, Px-104, PF-05221304, Oltipraz, FM101, Efinopegdutide 20 mg/mL, NRL972, Evogliptin, LCQ908, MN-001, GSK4532990, TVB-2640, IDN-6556, Lanifibranor, Exenatide, BI 1467335, and others
• The Non-Alcoholic Fatty Liver Disease epidemiology based on gender analyzed that overall NAFLD prevalence is higher in men than in women
• The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

Non-Alcoholic Fatty Liver Disease Overview
The phrase "non-alcoholic fatty liver disease" (NAFLD) refers to the complete range of fatty liver disease, from mild steatosis to more advanced steatosis with hepatitis, fibrosis, cirrhosis, and in some cases, hepatocellular cancer.

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:
The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Non-Alcoholic Fatty Liver Disease
• Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
• Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
• Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies
• Lanifibranor: Inventiva Pharma
• Tirzepatide: Eli Lilly and Company
• MGL-3196: Madrigal Pharmaceuticals, Inc.
• Obeticholicacid (OCA): Intercept Pharmaceuticals
• Pegozafermin: 89bio, Inc.
• SAMe 1000mg: Abbott
• Resmetirom: Madrigal Pharmaceuticals
• K-877: Kowa Company, Ltd.
• HL tablet: Huons Co., Ltd.
• Px-104: Phenex Pharmaceuticals
• PF-05221304: Pfizer
• Oltipraz: PharmaKing
• FM101: Future Medicine
• Efinopegdutide 20 mg/mL: Merck Sharp & Dohme
• NRL972: Norgine
• Evogliptin: Dong-A ST Co., Ltd.
• LCQ908: Novartis
• MN-001: MediciNova
• GSK4532990: GlaxoSmithKline
• TVB-2640: Sagimet Biosciences Inc.
• IDN-6556: Conatus Pharmaceuticals
• Lanifibranor: Inventiva Pharma
• Exenatide: Amylin Pharma
• BI 1467335: Boehringer Ingelheim

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Market Drivers
• Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

Non-Alcoholic Fatty Liver Disease Market Barriers
• Lucrative opportunities for the market growth in Unites States, owing to presence of large pool of patients suffering from NASH

Scope of the Non-Alcoholic Fatty Liver Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Abbott, Madrigal Pharmaceuticals, Kowa Company, Ltd., Huons Co., Ltd., Phenex Pharmaceuticals, Pfizer, PharmaKing, Future Medicine, Merck Sharp & Dohme, Norgine, Dong-A ST Co., Ltd., Novartis, MediciNova, GlaxoSmithKline, Sagimet Biosciences Inc., Conatus Pharmaceuticals, Inventiva Pharma, Amylin Pharma, Boehringer Ingelheim, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Obeticholicacid (OCA), Pegozafermin, SAMe 1000mg, Resmetirom, K-877, HL tablet, Px-104, PF-05221304, Oltipraz, FM101, Efinopegdutide 20 mg/mL, NRL972, Evogliptin, LCQ908, MN-001, GSK4532990, TVB-2640, IDN-6556, Lanifibranor, Exenatide, BI 1467335, and others
• Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit @ Non-Alcoholic Fatty Liver Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Alcoholic Fatty Liver Disease Market Report Introduction
2. Executive Summary for Non-Alcoholic Fatty Liver Disease
3. SWOT analysis of Non-Alcoholic Fatty Liver Disease
4. Non-Alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance
5. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance
6. Non-Alcoholic Fatty Liver Disease Disease Background and Overview
7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Alcoholic Fatty Liver Disease
9. Non-Alcoholic Fatty Liver Disease Current Treatment and Medical Practices
10. Non-Alcoholic Fatty Liver Disease Unmet Needs
11. Non-Alcoholic Fatty Liver Disease Emerging Therapies
12. Non-Alcoholic Fatty Liver Disease Market Outlook
13. Country-Wise Non-Alcoholic Fatty Liver Disease Market Analysis (2019-2032)
14. Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies
15. Non-Alcoholic Fatty Liver Disease Market Drivers
16. Non-Alcoholic Fatty Liver Disease Market Barriers
17. Non-Alcoholic Fatty Liver Disease Appendix
18. Non-Alcoholic Fatty Liver Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Non-Alcoholic Fatty Liver Disease Pipeline https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Alcoholic Fatty Liver Disease market. A detailed picture of the Non-Alcoholic Fatty Liver Disease pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Fatty Liver Disease treatment guidelines.
Non-Alcoholic Fatty Liver Disease Epidemiology https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Alcoholic Fatty Liver Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.